- Insulin resistance symptoms in females are often absent at first. The clearest signs are dark, velvety skin patches (acanthosis nigricans), a waist over 35 inches, and PCOS signs such as irregular periods or extra facial hair.
- Insulin resistance is common: 39.5% of US women ages 18 to 44 without diabetes had it in 2015 to 2018. PCOS and pregnancy raise the odds, and belly fat increases during the menopause transition.
- No routine test diagnoses insulin resistance itself. Providers use A1C, fasting glucose or a glucose tolerance test to find prediabetes. Fasting insulin and HOMA-IR scores have no universal cutoff.
- Activity and weight loss are first-line for insulin resistance. In the Diabetes Prevention Program, aiming for 7% weight loss and 150 active minutes a week cut diabetes risk 58%. No drug is FDA-approved for it.
Insulin resistance in women often starts quietly. Maybe you've noticed dark patches on your neck, a waistline that keeps growing, or periods that come and go, or a blood test came back "borderline."
This guide covers the insulin resistance symptoms in females worth checking, how PCOS, pregnancy and menopause change the picture, which tests to ask for, and what treatment looks like. We used the 2026 American Diabetes Association (ADA) Standards of Care, CDC and NIH data, FDA drug labels and the 2023 international PCOS guideline.
Read on to learn what the signs mean and what to do next.
What is insulin resistance?
Insulin resistance is when your muscle, fat and liver cells don't respond well to insulin, the hormone that moves sugar from your blood into your cells.
Blood sugar can stay normal with insulin resistance for a long time, because the pancreas makes extra insulin to make up for the weak response [30, 40].
Here's how it unfolds:
- Blood sugar rises after you eat: The pancreas releases insulin to move that sugar into cells for energy.
- Cells respond less: With insulin resistance, muscle, fat and liver cells need more insulin to do the same job.
- The pancreas works harder: It makes extra insulin to keep blood sugar in range. If it can't keep up, blood sugar rises into the prediabetes range and later the type 2 diabetes range [30, 40].
Insulin resistance is usually not diagnosed on its own, because the test for it is used mainly in research [30]. Providers diagnose prediabetes or type 2 diabetes instead, using blood sugar tests.
Insulin resistance affects 40.3% of US adults ages 18 to 44 without diabetes and 39.5% of young women, based on NHANES national survey data from 2015 to 2018 [33]. That study of 6,247 adults defined it as a HOMA-IR score of 2.5 or higher, a score calculated from fasting insulin and fasting glucose.
Insulin resistance is also rising. In NHANES, among US adults 20 and older without diabetes, the share with the condition grew from 24.8% in 1999 to 2000 to 38.4% in 2017 to 2018 [52]. Women's rates climbed faster than men's over those years [52].
What causes insulin resistance?
Researchers don't fully understand what causes insulin resistance, according to the National Institutes of Health (NIH). But extra weight, especially a large waist, and physical inactivity make it more likely, along with these other risk factors [30]:
- Overweight or a large waist: Extra weight, especially a large waist, raises the risk [30]. Belly fat is strongly linked to insulin resistance [21].
- Physical inactivity: Not being physically active raises the risk [30].
- Age and family history: Being 35 or older, or having a parent or sibling with diabetes, raises the risk [1, 30].
- Hormone conditions: PCOS, Cushing's syndrome and acromegaly (too much growth hormone) are linked to insulin resistance [30].
- Sleep apnea: Breathing pauses during sleep raise the risk [30].
- Short sleep: In a small 2012 lab study of 7 healthy adults, 4 days of only 4.5 hours in bed each night cut whole-body insulin sensitivity by 16% [4].
- Certain medicines: Long-term use of steroid medicines (glucocorticoids), some antipsychotics and some HIV medicines raises the risk of insulin resistance, according to the NIH [30]. The ADA adds statins and thiazide diuretics (a type of water pill) [1].
- Smoking: Smoking, vaping and secondhand smoke all raise the risk [30].
For more on weight as a risk factor, see our guide to obesity causes and treatment.
Who is more likely to have insulin resistance?
Women who had gestational diabetes, gave birth to a baby weighing 9 pounds or more, or have PCOS are more likely to have insulin resistance [30]. Risk is also higher in some groups: people who are African American, American Indian, Asian American, Hispanic, Latino or Pacific Islander [30].
What are insulin resistance symptoms in females?
Most women with insulin resistance have no symptoms [30]. Early on, the pancreas makes extra insulin and keeps blood sugar normal [40].
When insulin resistance signs do appear in women, the best-supported are acanthosis nigricans, a waist over 35 inches, many skin tags and PCOS signs. The table sorts common signs by strength of evidence.
| Sign | What it looks like | Strength of the link | What it can mean |
|---|---|---|---|
| Acanthosis nigricans | Dark, thick, velvety skin in body folds such as the neck, armpits and groin, or over finger and toe joints [25] | Strong. The ADA lists it as a condition tied to insulin resistance [1] | Get your blood sugar tested. Patches that develop fast and spread widely need prompt review, because they can be linked to cancer [25] |
| Waist over 35 inches | Weight carried around the belly rather than the hips | Strong. Belly fat is strongly linked to insulin resistance [21], and over 35 inches is a metabolic syndrome criterion for women [28] | A reason to get blood sugar tested |
| Many skin tags | Small, soft flaps of skin, often on the neck or in the armpits | Limited. Linked to insulin resistance in small case-control studies, but not proof on their own [42] | Worth mentioning at a checkup, especially with other signs |
| PCOS signs | Irregular or missed periods, acne, extra hair on the face, chest or belly | Strong. Insulin resistance is a key feature of PCOS [43] | Ask about PCOS and blood sugar testing |
| Lab and office findings | High triglycerides, low HDL (good) cholesterol, high blood pressure | Strong as a group. They make up metabolic syndrome, also called insulin resistance syndrome [29] | Ask whether you meet the metabolic syndrome criteria (see the FAQ) |
| Thirst, peeing often, blurry vision, tiredness, frequent infections | New or worse over weeks to months | These are signs that blood sugar is already high, as in diabetes [7] | Get tested soon |
| Cravings, constant hunger, brain fog, sleepiness after meals | Often listed online as insulin resistance symptoms | Weak. We found no studies showing these can identify insulin resistance | They have many possible causes. A blood test gives the answer |
Signs of insulin resistance in women, from strongest to weakest evidence.
Acanthosis nigricans: Dark, velvety skin on the neck, armpits or groin, called acanthosis nigricans, is often linked to insulin resistance, but it is not proof on its own [25]. The ADA lists it as a reason for earlier diabetes testing in people with overweight [1].
If you have dark skin patches, a waist over 35 inches or PCOS signs, ask your provider for an A1C, fasting glucose or glucose tolerance test.
How do you feel if you are insulin resistant?
Most women with insulin resistance feel normal. Type 2 diabetes symptoms often take years to develop and are hard to spot [7], so a blood test is often how people find out.
Insulin resistance and prediabetes often go unnoticed. About 8 in 10 US adults with prediabetes don't know they have it, the CDC reports [8]. Only 25.2% of women with prediabetes have been told by a health professional [8].
Does insulin resistance cause belly fat and weight gain?
Insulin resistance can lead to weight gain, the NIH notes, and extra belly fat is strongly tied to the condition [30, 21]. Be wary of products that promise to "fix" it and melt belly fat.
Losing weight improves insulin resistance. In a trial of 40 adults with obesity, losing about 5% of body weight improved insulin sensitivity in the liver, muscle and fat tissue [19].
How does insulin resistance affect women at different life stages?
Insulin resistance is a key feature of PCOS and rises naturally in late pregnancy [43, 5]. In the menopause transition, belly fat deep around the organs grows faster, and that kind of fat is strongly linked to the condition [13, 21].
| Life stage | What happens to insulin | Signs to watch | What to ask for |
|---|---|---|---|
| PCOS (any age after puberty) | Insulin resistance is a key feature, even in lean women [43, 38] | Irregular periods, acne, extra facial or body hair, dark skin patches | A blood sugar check at diagnosis, then every 1 to 3 years [43] |
| Pregnancy | Insulin sensitivity fell by about half by late pregnancy in a small study [5] | Usually none; gestational diabetes is found by testing | With PCOS, a glucose tolerance test at 24 to 28 weeks [43]. After gestational diabetes, the same test 4 to 12 weeks after birth [1] |
| Perimenopause and menopause | Belly fat deep around the organs grows faster [13] | A growing waist | Diabetes screening from age 35, at least every 3 years [1] |
Insulin resistance and PCOS
Insulin resistance is a key feature of polycystic ovary syndrome (PCOS), which affects 10% to 13% of women of reproductive age [43]. In 2026, PCOS got a new name, polyendocrine metabolic ovarian syndrome (PMOS), after a global process with 56 groups and more than 22,000 survey respondents [44].
We use "PCOS" here because it's the name most people still search for.
Insulin resistance appears to be part of PCOS itself, not just a result of extra weight [38]. The PCOS guideline calls it a pathophysiological factor, meaning part of how PCOS develops [43].
Insulin resistance shows up in women with PCOS at every size. A small study used a clamp test, the research gold standard that measures how much sugar the body clears at a fixed insulin level [33, 38]. It found the condition in 75% of lean women with PCOS and 95% of women with PCOS and overweight [38].
In the same study, 62% of women with overweight but without PCOS had insulin resistance [38]. Extra weight raised it more in women with PCOS than in women without it, the authors reported. Each group had only 14 to 20 women.
The 2023 international PCOS guideline says women with PCOS have a higher risk of prediabetes and type 2 diabetes regardless of age or weight [43]. It recommends checking blood sugar at diagnosis and every 1 to 3 years, and it calls the 2-hour oral glucose tolerance test (OGTT) the most accurate test in PCOS [43].
The 2023 international PCOS guideline does not recommend routine insulin blood tests, calling them of limited use in everyday care [43]. For treatment options, see our guide to GLP-1 medications for PCOS.
Insulin resistance in pregnancy and gestational diabetes
Insulin resistance rises naturally during pregnancy. In a small study of 6 women without obesity, insulin sensitivity fell 56% by weeks 34 to 36 [5]. Gestational diabetes is high blood sugar that first shows up during pregnancy.
Gestational diabetes does not mean you will get type 2 diabetes, but it raises the odds. A 2020 BMJ review of 20 studies with over 1.3 million women found nearly 10 times higher risk afterward [51]. The ADA advises a glucose tolerance test 4 to 12 weeks after birth, then screening every 1 to 3 years for life [1].
If you take a GLP-1 medicine and plan a pregnancy, read what GLP-1 labels say about pregnancy.
Insulin resistance in perimenopause and menopause
During the menopause transition, belly fat stored deep around the organs (visceral fat) grows faster [13], and belly fat is strongly linked to insulin resistance [21].
In the SWAN study of 380 women followed for a median of 11.8 years, visceral fat rose 6.24% a year once the transition began [13]. That rate is for White women, the study's reference group.
Whether menopause itself raises insulin resistance is less clear: a 2022 review called the evidence mixed [21]. Menopausal hormone therapy is not used to prevent diabetes. Women's Health Initiative researchers said estrogen should not be used that way [3].
How do you test for insulin resistance?
There's no single routine test for insulin resistance. Health care providers usually order blood sugar tests that diagnose prediabetes and diabetes, because the direct test is used mainly in research [30]. Here's how the common options compare.
| Test | What it measures | Prediabetes range | Diabetes range | Good to know |
|---|---|---|---|---|
| A1C (hemoglobin A1C) | Average blood sugar over the past few months | 5.7% to 6.4% | 6.5% or higher | No fasting needed. Anemia, some hemoglobin types, pregnancy and kidney failure can skew it [1] |
| Fasting plasma glucose | Blood sugar after at least 8 hours without food or drinks with calories | 100 to 125 mg/dL | 126 mg/dL or higher | A simple morning blood draw [1] |
| 2-hour oral glucose tolerance test (OGTT) | Blood sugar 2 hours after a 75-gram sugar drink | 140 to 199 mg/dL | 200 mg/dL or higher | The most accurate blood sugar test in PCOS [43] |
| Fasting insulin | Insulin level after fasting | No standard range | Not used to diagnose | Insulin tests from different makers are not standardized [20] |
| HOMA-IR | A score calculated from fasting insulin and fasting glucose | No universal cutoff | Not used to diagnose | Mainly a research tool (see below) |
| Triglyceride-to-HDL ratio | A ratio from a standard cholesterol test | A ratio of 3.0 or higher is a clue in adults with overweight [23] | Not used to diagnose | Caught 64% of adults with insulin resistance in one study and did not work in African American adults [23, 39] |
| Waist size | Belly fat | Over 35 inches is a warning sign for women [28] | Not used to diagnose | Easy to check at home |
| Glucose clamp | How much sugar the body clears at a fixed insulin level | Research only | Not used to diagnose | The research gold standard [33] |
Prediabetes and diabetes ranges from the ADA Standards of Care 2026. A diabetes diagnosis needs two abnormal results unless blood sugar is clearly very high [1].
What is HOMA-IR, and is it reliable?
HOMA-IR (homeostatic model assessment of insulin resistance) is a score calculated from fasting insulin and fasting glucose. It's useful for studying large groups, but it's not reliable enough to diagnose one person.
The HOMA-IR formula is fasting insulin (in µU/mL) times fasting glucose (in mg/dL), divided by 405 [33]. Its creators reported a coefficient of variation of 31%, which means the estimate for one person can swing a lot [22]. Studies also use different cutoffs, such as 2.5, 2.6 or 3.8 [33, 52, 42].
Good to know
A high HOMA-IR or fasting insulin result is a reason to ask your provider about an A1C or glucose tolerance test. It is not a diagnosis on its own.
Can you check for insulin resistance at home?
No home test can diagnose insulin resistance, but you can track a few clues at home and then confirm with a lab test:
- Measure your waist: Over 35 inches is a warning sign for women [28].
- Use a home A1C kit with care: It can't diagnose prediabetes. The ADA says a diagnostic A1C must come from a certified lab method or an FDA-approved device in a certified lab [1].
- Know what a CGM can't do: In March 2024, the FDA cleared the first over-the-counter continuous glucose monitor (CGM), Dexcom Stelo, for adults who don't use insulin [46]. A CGM tracks glucose, not insulin, and the ADA says CGMs aren't proven for screening or diagnosis [1].
When should women get screened for prediabetes and diabetes?
Insulin resistance has no routine test, so screening for prediabetes and diabetes is the practical check. The ADA advises screening for all adults from age 35, repeated at least every 3 years if results are normal [1]. Some women need testing earlier or more often:
- Earlier, at any age: if you have overweight plus a risk factor such as PCOS, a parent or sibling with diabetes, high blood pressure or acanthosis nigricans [1]. Overweight here means a BMI of 25 or higher, or 23 or higher for people of Asian ancestry.
- Ages 35 to 70 with overweight or obesity: the US Preventive Services Task Force (USPSTF) recommends screening, with a grade B rating [49].
- After gestational diabetes: every 1 to 3 years for life [1].
- With PCOS: at diagnosis, then every 1 to 3 years [43].
- With prediabetes: every year [1].
Questions to ask at your appointment:
- Which test will you use: A1C, fasting glucose or a glucose tolerance test?
- Do my PCOS, pregnancy history or family history mean I need a glucose tolerance test?
- Should we check my triglycerides, HDL, blood pressure and waist for metabolic syndrome?
- When should I be tested again?
Related reading • GLP-1 medications for PCOS: the evidence: What research shows about GLP-1 medicines in women with PCOS. • Type 2 diabetes: treatment options explained: The main medicine and lifestyle choices once diabetes is diagnosed. • Obesity: causes and treatment options: Why weight builds up and which treatments are FDA-approved. • What is GLP-1? A beginner guide: How GLP-1 medicines work on appetite and blood sugar.
Is insulin resistance the same as prediabetes or type 2 diabetes?
No, insulin resistance is not the same as prediabetes or type 2 diabetes, and you can have it without either, often while blood sugar is still normal [30, 40].
The three are stages on one path: prediabetes follows when blood sugar rises above normal, and type 2 diabetes when it rises further [30, 40].
| Feature | Insulin resistance | Prediabetes | Type 2 diabetes |
|---|---|---|---|
| What's happening | Cells respond poorly to insulin, so the pancreas makes extra | The pancreas can't fully keep up, and blood sugar is above normal | Blood sugar stays high |
| Blood sugar | Usually normal | A1C 5.7% to 6.4%, or fasting glucose 100 to 125 mg/dL | A1C 6.5% or higher, or fasting glucose 126 mg/dL or higher |
| How it's found | No routine test. Signs and risk factors point to it | A1C, fasting glucose or OGTT | The same tests, confirmed |
| How common in the US | About 4 in 10 adults ages 18 to 44 without diabetes (NHANES) [33] | 115.2 million adults (43.5%), including 39.3% of women (CDC, 2026) [8] | 40.1 million people (12.0%) (CDC, 2026) [8] |
| Can it improve? | Often, with activity and weight loss | Yes. Many people return to normal blood sugar | It can be managed with lifestyle changes and medicine |
Ranges from the ADA Standards of Care 2026 [1].
Insulin resistance turns into diabetes gradually, through prediabetes. Each year, about 5% to 10% of people with prediabetes progress to diabetes, and a similar share return to normal blood sugar, a 2012 Lancet review found [40]. An ADA expert panel estimated that up to 70% eventually develop diabetes [40].
Your A1C helps show your risk: an A1C of 6.0% to 6.4% carries a 25% to 50% chance of diabetes within 5 years [1].
Diabetes is often missed, too: CDC data show 27.6% of US adults with diabetes are undiagnosed [8]. If you already have a diagnosis, read about type 2 diabetes treatment options.
What can insulin resistance lead to?
Untreated insulin resistance raises the risk of type 2 diabetes and is linked to high blood pressure, fatty liver disease and heart disease [30, 12].
- Type 2 diabetes: the most direct risk, because insulin resistance comes before prediabetes and type 2 diabetes on the same path [40].
- Heart disease and stroke: In people without diabetes, higher HOMA-IR scores were linked to a 64% higher risk of coronary heart disease in a review of 65 studies [12]. Metabolic syndrome, the cluster of risk factors tied to insulin resistance, carried about twice the risk of cardiovascular disease across 87 studies [26].
- Fatty liver disease: now called metabolic dysfunction-associated steatotic liver disease (MASLD), formerly NAFLD. Its 2023 definition is built on risk factors tied to insulin resistance [35].
- High blood pressure and unhealthy cholesterol: both are linked to insulin resistance [30].
How do you reverse insulin resistance? What helps most
Insulin resistance can often be improved, and sometimes reversed, with more physical activity and modest weight loss [30]. These lifestyle steps are also the ADA's main approach to preventing type 2 diabetes [2].
Exercise acts fastest: one session can raise insulin sensitivity for 2 to 72 hours in people with type 2 diabetes, an American College of Sports Medicine statement reports [16].
The strongest proof that lifestyle change works comes from the Diabetes Prevention Program, a trial of 3,234 adults with prediabetes, 68% of them women [18]. People who aimed for at least 7% weight loss and 150 minutes of weekly activity cut their diabetes risk by 58% over about 3 years [18].
Lifestyle gains can last: in the Diabetes Prevention Program, the lifestyle group's diabetes risk was still 27% lower after 15 years [9].
- Move most days: Aim for 150 minutes a week of moderate activity, like brisk walking. Add strength training 2 to 3 days a week, not on back-to-back days [16].
- Lose 5% to 7% of your weight if you have extra weight: The ADA recommends this goal for adults at high risk of diabetes [2]. For a 180-pound woman, 5% is 9 pounds.
- Choose a proven eating pattern you can keep: For insulin resistance, start with the ADA advice for prediabetes: a pattern such as Mediterranean, plant-based, DASH or low-carbohydrate [2]. Limit refined and processed foods: diets low in them and rich in whole grains, legumes, nuts, fruits and vegetables are linked to lower diabetes risk [2].
- Protect your sleep: Short sleep lowers insulin sensitivity, as a small lab study showed [4]. Loud snoring and daytime sleepiness are worth checking for sleep apnea, a known risk factor [30].
- Quit smoking and vaping: Both, plus secondhand smoke, raise the risk [30].
- Review your medicines: Some, such as steroids and certain antipsychotics, raise blood sugar risk, often by promoting insulin resistance [1]. Don't stop any medicine on your own. Ask your provider about options.
How long does it take to improve insulin resistance?
Insulin resistance can start to improve within hours of exercise, but lab results lag. Expect a few months for weight-loss gains, and a few months more before your A1C reflects the change.
| Time frame | What can change | Evidence |
|---|---|---|
| Hours to 3 days | Insulin sensitivity after a single exercise session | ACSM consensus statement [16] |
| About 3 to 4 months | Insulin sensitivity in liver, muscle and fat after about 5% weight loss | Small randomized trial; median 3.5 months to reach 5% [19] |
| A few months | A1C, which reflects average blood sugar over the past few months | ADA Standards of Care [1] |
| About 3 to 15 years | Lower diabetes risk with lasting habits | Diabetes Prevention Program [18, 9] |
What are signs insulin resistance is improving?
No routine test tracks insulin resistance directly, so the best signs it is improving come from tests your provider already orders. If your A1C or fasting glucose was in the prediabetes range, a return to under 5.7% and under 100 mg/dL means blood sugar is back to normal [1].
A smaller waist and better triglyceride and HDL levels are good signs, too.
What medications and supplements help insulin resistance?
No medicine is FDA-approved to treat insulin resistance itself or to prevent type 2 diabetes [2, 10, 11, 31, 32, 36, 41]. Still, some medicines helped in trials. Metformin, Wegovy® (semaglutide), Zepbound® (tirzepatide) and Actos (pioglitazone) improved insulin sensitivity or cut diabetes risk [18, 34, 15, 17].
Wegovy® is a GLP-1 medicine, and Zepbound® is a GIP and GLP-1 medicine. Providers may prescribe these medicines for a separate approved reason, or off-label, which means for a use the FDA label doesn't cover.
| Medicine | FDA-approved for | What research shows | Cautions for women |
|---|---|---|---|
| Metformin | Type 2 diabetes in adults and children 10 and older [36] | Cut new diabetes cases by 31% in the Diabetes Prevention Program, a trial of 3,234 adults with prediabetes followed for about 3 years [18] | Off-label for insulin resistance and PCOS. Stomach upset is common. Rare lactic acidosis (a dangerous buildup of acid in the blood) carries a boxed warning [36] |
| Wegovy® (semaglutide), a GLP-1 medicine | Reducing and keeping off excess weight in adults with obesity, children 12+ with obesity (injection only), or adults with overweight plus a weight-related condition. Also lowers heart attack, stroke and heart death risk in adults with heart disease and obesity or overweight, and treats noncirrhotic MASH (fatty liver disease with liver inflammation) with moderate to advanced scarring (injection, accelerated approval) [32] | In the STEP 1 trial of 1,961 adults with obesity or overweight, 84.1% of those with prediabetes reached normal blood sugar by 68 weeks, vs 47.8% on placebo [34] | Stop at least 2 months before a planned pregnancy. Boxed warning for thyroid C-cell tumors (a type of thyroid tumor) seen in rodents [32] |
| Zepbound® (tirzepatide), a GIP and GLP-1 medicine | Long-term weight reduction in adults who qualify, and moderate to severe obstructive sleep apnea with obesity [11] | In the SURMOUNT-1 trial of 2,539 adults with obesity or overweight, fasting insulin fell 46.9% vs 9.7% on placebo at 72 weeks [48]. Among 1,032 participants with prediabetes, 1.3% developed type 2 diabetes over about 3 years, vs 13.3% on placebo [15] | Can make birth control pills work less well: add a backup or switch to a non-oral method for 4 weeks after starting and after each dose increase. Same thyroid boxed warning [11] |
| Ozempic® (semaglutide) and Mounjaro® (tirzepatide) | Type 2 diabetes, with added heart or kidney benefits in type 2 diabetes. Not approved for weight loss [31, 10] | Same active ingredients as Wegovy® and Zepbound®, but approved for a different use; the trial results above used Wegovy® and Zepbound® doses [31, 32] | Use for insulin resistance alone is off-label. Same thyroid boxed warning [31, 10] |
| Actos (pioglitazone) | Type 2 diabetes in adults [41] | Lowers insulin resistance in muscle and liver [41]. In the IRIS trial of 3,876 people with insulin resistance after a stroke or mini-stroke (TIA), new diabetes over about 5 years fell from 7.7% to 3.8% [17] | Boxed warning for heart failure. More bone fractures in women [41] |
FDA indications as of October 2026. Your prescriber sets and adjusts any dose.
Metformin may help if you have prediabetes but not diabetes: it cut new diabetes cases 31% in the Diabetes Prevention Program, though it's off-label for insulin resistance [18, 36]. The ADA says it can be considered for some high-risk adults, including women who had gestational diabetes [2].
For insulin resistance with PCOS, the 2023 international guideline leans toward metformin: it says metformin should be considered at a BMI of 25 or higher [43]. Weight-loss medicines such as semaglutide could be considered, along with lifestyle changes, and women taking them should use effective birth control [43].
Learn what GLP-1 medicines are and how Zepbound® vs. Wegovy® compare.
Do supplements like inositol, berberine or magnesium help insulin resistance?
Supplements for insulin resistance have limited and mixed evidence, and the FDA doesn't approve dietary supplements before they're sold [47]. Here's what the research shows:
- Inositol: A review of 9 trials with about 500 women with PCOS found myo-inositol lowered HOMA-IR [45]. A larger review of 26 trials with 1,691 patients found no HOMA-IR or fasting insulin benefit over placebo [14].
- Inositol guidance: The PCOS guideline calls the benefits limited and recommends no type or dose [43].
- Berberine: A review of 20 trials found it lowered HOMA-IR by 0.85 points in the 12 trials that measured it [53]. Of the 20 trials, 17 were in Asian populations. It can cause stomach upset, interact with medicines, and may be unsafe in pregnancy or while breastfeeding [27].
- Magnesium: Results are mixed. A review of randomized trials found magnesium lowered HOMA-IR by about 0.67 points overall, with larger benefits when taken for 4 months or more [37]. A review of 18 trials found only a trend in people at high risk of diabetes [50].
Tell your provider about any supplement you take, especially if you also take a diabetes medicine.
When should you see a healthcare provider about insulin resistance?
See a health care provider about insulin resistance if you have a sign, a major risk factor, or symptoms of high blood sugar. Finding it before diabetes develops gives lifestyle changes the best chance to work. Make an appointment if you have:
- Acanthosis nigricans: dark, velvety skin patches, especially if they develop fast or spread widely [25]
- PCOS signs: irregular or missed periods, acne or new facial hair
- Past gestational diabetes: and no blood sugar test in the last 3 years [1]
- Age 35 or older: and no diabetes screening yet [1]
- High blood sugar symptoms: thirst, frequent peeing, blurry vision or frequent infections [7]
- Pregnancy plans with PCOS: a blood sugar check before pregnancy [43]
A primary care provider, such as a doctor, physician assistant or nurse practitioner, can order these tests [30].
Call 911 or go to the nearest ER if your blood sugar stays at 300 mg/dL or above or your breath smells fruity [6]. Do the same if you're vomiting and can't keep food or drinks down, or you have trouble breathing [6]. Very high blood sugar with confusion, extreme thirst, seizures or passing out is also an emergency [24].
Bottom line
- Insulin resistance usually has no symptoms. The clearest clues in women are dark, velvety skin patches, a waist over 35 inches and PCOS signs.
- PCOS, past gestational diabetes and the belly-fat gain of the menopause transition raise the odds, so screening matters at these stages.
- Ask for an A1C, fasting glucose or glucose tolerance test. HOMA-IR is a research estimate, not a diagnosis.
- Activity and modest weight loss come first. Medicines such as metformin or GLP-1 medications for weight loss are used off-label or for a separate approved reason.
Frequently asked questions
Can thin women have insulin resistance?
Yes, thin women can have insulin resistance, especially women with PCOS, who have higher diabetes risk at any weight [43]. In national NHANES data, nearly half of young adults with the condition did not have obesity [33]. A normal weight doesn't rule it out, so testing still makes sense if you have other signs or risk factors.
What is a normal fasting insulin level?
No single normal fasting insulin level exists, so a fasting insulin result can't confirm insulin resistance on its own. In an ADA workgroup study, 12 insulin tests from 9 makers did not agree well: variation between tests ranged from 12% to 66% [20]. That's one reason the PCOS guideline doesn't recommend routine insulin tests [43].
Is insulin resistance the same as metabolic syndrome?
Not exactly: insulin resistance means cells respond poorly to insulin. Metabolic syndrome is a group of linked risk factors [29]. Women may have metabolic syndrome with 3 or more of 5 [29]. These are a waist over 35 inches, triglycerides over 150 mg/dL, HDL below 50 mg/dL, blood pressure of 130/85 or higher, and fasting glucose of 100 mg/dL or higher [28].
Does Ozempic® help with insulin resistance?
Ozempic® and Wegovy® (semaglutide) aren't FDA-approved for insulin resistance, but in the STEP 1 trial, 84.1% of people with prediabetes on Wegovy® reached normal blood sugar [34]. That was by 68 weeks, vs 47.8% on placebo. Ozempic® is approved for type 2 diabetes, not weight loss [31]. Using either for this purpose alone is off-label.
What kind of doctor treats insulin resistance?
A primary care provider, such as a doctor, physician assistant or nurse practitioner, can check your insulin resistance risk factors [30]. They can also order A1C or glucose tests for prediabetes. Your provider may also send you to an OB-GYN for PCOS or pregnancy care, or to an endocrinologist (a hormone doctor).
peptides.io relies on primary sources: FDA drug labels, federal health agencies, clinical guidelines and peer-reviewed studies. Read our editorial policy.
Sources
- 1. American Diabetes Association Professional Practice Committee for Diabetes. (2026a). 2. Diagnosis and classification of diabetes: Standards of care in diabetes 2026. Diabetes Care, 49(Suppl. 1), S27-S49. https://doi.org/10.2337/dc26-S002
- 2. American Diabetes Association Professional Practice Committee for Diabetes. (2026b). 3. Prevention or delay of diabetes and associated comorbidities: Standards of care in diabetes 2026. Diabetes Care, 49(Suppl. 1), S50-S60. https://doi.org/10.2337/dc26-S003
- 3. Bonds, D. E., Lasser, N., Qi, L., Brzyski, R., Caan, B., Heiss, G., Limacher, M. C., Liu, J. H., Mason, E., Oberman, A., O'Sullivan, M. J., Phillips, L. S., Prineas, R. J., & Tinker, L. (2006). The effect of conjugated equine oestrogen on diabetes incidence: The Women's Health Initiative randomised trial. Diabetologia, 49(3), 459-468. https://doi.org/10.1007/s00125-005-0096-0
- 4. Broussard, J. L., Ehrmann, D. A., Van Cauter, E., Tasali, E., & Brady, M. J. (2012). Impaired insulin signaling in human adipocytes after experimental sleep restriction: A randomized, crossover study. Annals of Internal Medicine, 157(8), 549-557. https://doi.org/10.7326/0003-4819-157-8-201210160-00005
- 5. Catalano, P. M., Tyzbir, E. D., Roman, N. M., Amini, S. B., & Sims, E. A. (1991). Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. American Journal of Obstetrics and Gynecology, 165(6 Pt 1), 1667-1672. https://doi.org/10.1016/0002-9378(91)90012-g
- 6. Centers for Disease Control and Prevention. (2024a). Diabetic ketoacidosis. Retrieved October 5, 2026, from https://www.cdc.gov/diabetes/about/diabetic-ketoacidosis.html
- 7. Centers for Disease Control and Prevention. (2024b). Symptoms of diabetes. Retrieved October 5, 2026, from https://www.cdc.gov/diabetes/signs-symptoms/index.html
- 8. Centers for Disease Control and Prevention. (2026). National diabetes statistics report. U.S. Department of Health and Human Services. Retrieved October 5, 2026, from https://www.cdc.gov/diabetes/php/data-research/index.html
- 9. Diabetes Prevention Program Research Group. (2015). Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: The Diabetes Prevention Program Outcomes Study. The Lancet Diabetes & Endocrinology, 3(11), 866-875. https://doi.org/10.1016/S2213-8587(15)00291-0
- 10. Eli Lilly and Company. (2026a). Mounjaro® (tirzepatide) injection: Prescribing information (Rev. 08/2026). Retrieved October 5, 2026, from https://pi.lilly.com/us/mounjaro-uspi.pdf
- 11. Eli Lilly and Company. (2026b). Zepbound® (tirzepatide) injection: Prescribing information (Rev. 08/2026). Retrieved October 5, 2026, from https://pi.lilly.com/us/zepbound-uspi.pdf
- 12. Gast, K. B., Tjeerdema, N., Stijnen, T., Smit, J. W., & Dekkers, O. M. (2012). Insulin resistance and risk of incident cardiovascular events in adults without diabetes: Meta-analysis. PLoS ONE, 7(12), e52036. https://doi.org/10.1371/journal.pone.0052036
- 13. Greendale, G. A., Han, W., Finkelstein, J. S., Burnett-Bowie, S. M., Huang, M., Martin, D., & Karlamangla, A. S. (2021). Changes in regional fat distribution and anthropometric measures across the menopause transition. The Journal of Clinical Endocrinology & Metabolism, 106(9), 2520-2534. https://doi.org/10.1210/clinem/dgab389
- 14. Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., Várbíró, S., & Horváth, E. M. (2023). Inositol is an effective and safe treatment in polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Reproductive Biology and Endocrinology, 21(1), 10. https://doi.org/10.1186/s12958-023-01055-z
- 15. Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., Bunck, M. C., Ahmad, N. N., & Jouravskaya, I. (2025). Tirzepatide for obesity treatment and diabetes prevention. New England Journal of Medicine, 392(10), 958-971. https://doi.org/10.1056/NEJMoa2410819
- 16. Kanaley, J. A., Colberg, S. R., Corcoran, M. H., Malin, S. K., Rodriguez, N. R., Crespo, C. J., Kirwan, J. P., & Zierath, J. R. (2022). Exercise/physical activity in individuals with type 2 diabetes: A consensus statement from the American College of Sports Medicine. Medicine & Science in Sports & Exercise, 54(2), 353-368. https://doi.org/10.1249/MSS.0000000000002800
- 17. Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., Brass, L. M., Schwartz, G. G., Adams, H. P., Jr., Berger, L., Carolei, A., Clark, W., Coull, B., Ford, G. A., Kleindorfer, D., ... Winder, T. R. (2016). Pioglitazone after ischemic stroke or transient ischemic attack. New England Journal of Medicine, 374(14), 1321-1331. https://doi.org/10.1056/NEJMoa1506930
- 18. Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., & Nathan, D. M. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346(6), 393-403. https://doi.org/10.1056/NEJMoa012512
- 19. Magkos, F., Fraterrigo, G., Yoshino, J., Luecking, C., Kirbach, K., Kelly, S. C., de las Fuentes, L., He, S., Okunade, A. L., Patterson, B. W., & Klein, S. (2016). Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metabolism, 23(4), 591-601. https://doi.org/10.1016/j.cmet.2016.02.005
- 20. Marcovina, S., Bowsher, R. R., Miller, W. G., Staten, M., Myers, G., Caudill, S. P., Campbell, S. E., & Steffes, M. W. (2007). Standardization of insulin immunoassays: Report of the American Diabetes Association Workgroup. Clinical Chemistry, 53(4), 711-716. https://doi.org/10.1373/clinchem.2006.082214
- 21. Marlatt, K. L., Pitynski-Miller, D. R., Gavin, K. M., Moreau, K. L., Melanson, E. L., Santoro, N., & Kohrt, W. M. (2022). Body composition and cardiometabolic health across the menopause transition. Obesity, 30(1), 14-27. https://doi.org/10.1002/oby.23289
- 22. Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985). Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7), 412-419. https://doi.org/10.1007/BF00280883
- 23. McLaughlin, T., Abbasi, F., Cheal, K., Chu, J., Lamendola, C., & Reaven, G. (2003). Use of metabolic markers to identify overweight individuals who are insulin resistant. Annals of Internal Medicine, 139(10), 802-809. https://doi.org/10.7326/0003-4819-139-10-200311180-00007
- 24. MedlinePlus. (2026a, January 25). Diabetic hyperglycemic hyperosmolar syndrome. National Library of Medicine. Retrieved October 5, 2026, from https://medlineplus.gov/ency/article/000304.htm
- 25. MedlinePlus. (2026b, April 9). Acanthosis nigricans. National Library of Medicine. Retrieved October 5, 2026, from https://medlineplus.gov/ency/article/000852.htm
- 26. Mottillo, S., Filion, K. B., Genest, J., Joseph, L., Pilote, L., Poirier, P., Rinfret, S., Schiffrin, E. L., & Eisenberg, M. J. (2010). The metabolic syndrome and cardiovascular risk: A systematic review and meta-analysis. Journal of the American College of Cardiology, 56(14), 1113-1132. https://doi.org/10.1016/j.jacc.2010.05.034
- 27. National Center for Complementary and Integrative Health. (2023, November). Berberine and weight loss: What you need to know. Retrieved October 5, 2026, from https://www.nccih.nih.gov/health/berberine-and-weight-loss-what-you-need-to-know
- 28. National Heart, Lung, and Blood Institute. (2022a, May 18). Metabolic syndrome: Diagnosis. Retrieved October 5, 2026, from https://www.nhlbi.nih.gov/health/metabolic-syndrome/diagnosis
- 29. National Heart, Lung, and Blood Institute. (2022b, May 18). What is metabolic syndrome? Retrieved October 5, 2026, from https://www.nhlbi.nih.gov/health/metabolic-syndrome
- 30. National Institute of Diabetes and Digestive and Kidney Diseases. (2025, March). Insulin resistance & prediabetes. Retrieved October 5, 2026, from https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance
- 31. Novo Nordisk. (2026a). Ozempic® (semaglutide) injection: Prescribing information (Rev. 05/2026). Retrieved October 5, 2026, from https://www.novo-pi.com/ozempic.pdf
- 32. Novo Nordisk. (2026b). Wegovy® (semaglutide) injection and Wegovy® (semaglutide) tablets: Prescribing information (Rev. 06/2026). Retrieved October 5, 2026, from https://www.novo-pi.com/wegovy.pdf
- 33. Parcha, V., Heindl, B., Kalra, R., Li, P., Gower, B., Arora, G., & Arora, P. (2022). Insulin resistance and cardiometabolic risk profile among nondiabetic American young adults: Insights from NHANES. The Journal of Clinical Endocrinology & Metabolism, 107(1), e25-e37. https://doi.org/10.1210/clinem/dgab645
- 34. Perreault, L., Davies, M., Frias, J. P., Laursen, P. N., Lingvay, I., Machineni, S., Varbo, A., Wilding, J. P. H., Wallenstein, S. O. R., & le Roux, C. W. (2022). Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program. Diabetes Care, 45(10), 2396-2405. https://doi.org/10.2337/dc21-1785
- 35. Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., Arrese, M., Bataller, R., Beuers, U., Boursier, J., Bugianesi, E., Byrne, C. D., Castro Narro, G. E., Chowdhury, A., Cortez-Pinto, H., ... Newsome, P. N. (2023). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology, 78(6), 1966-1986. https://doi.org/10.1097/HEP.0000000000000520
- 36. ScieGen Pharmaceuticals. (2026). Metformin hydrochloride tablets: Prescribing information (Rev. 6/2026). DailyMed. Retrieved October 5, 2026, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e4c4ba9-65c6-4273-8f6b-2423ab521dad
- 37. Simental-Mendía, L. E., Sahebkar, A., Rodríguez-Morán, M., & Guerrero-Romero, F. (2016). A systematic review and meta-analysis of randomized controlled trials on the effects of magnesium supplementation on insulin sensitivity and glucose control. Pharmacological Research, 111, 272-282. https://doi.org/10.1016/j.phrs.2016.06.019
- 38. Stepto, N. K., Cassar, S., Joham, A. E., Hutchison, S. K., Harrison, C. L., Goldstein, R. F., & Teede, H. J. (2013). Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Human Reproduction, 28(3), 777-784. https://doi.org/10.1093/humrep/des463
- 39. Sumner, A. E., Finley, K. B., Genovese, D. J., Criqui, M. H., & Boston, R. C. (2005). Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Archives of Internal Medicine, 165(12), 1395-1400. https://doi.org/10.1001/archinte.165.12.1395
- 40. Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012). Prediabetes: A high-risk state for diabetes development. The Lancet, 379(9833), 2279-2290. https://doi.org/10.1016/S0140-6736(12)60283-9
- 41. Takeda Pharmaceuticals America. (2025). Actos (pioglitazone) tablets: Prescribing information (Rev. 03/2025). DailyMed. Retrieved October 5, 2026, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c
- 42. Tamega, A. de A., Aranha, A. M., Guiotoku, M. M., Miot, L. D., & Miot, H. A. (2010). Associação entre acrocórdons e resistência à insulina [Association between skin tags and insulin resistance]. Anais Brasileiros de Dermatologia, 85(1), 25-31. https://doi.org/10.1590/s0365-05962010000100003
- 43. Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 108(10), 2447-2469. https://doi.org/10.1210/clinem/dgad463
- 44. Teede, H. J., Saadati, S., Morman, R., Khomami, M. B., Cree, M. G., Norman, R. J., & Piltonen, T. (2026). From polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome: A systematic search and historical account of the renaming of polycystic ovary syndrome. Fertility and Sterility. Advance online publication. https://doi.org/10.1016/j.fertnstert.2026.08.1122
- 45. Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. (2017). Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials. Endocrine Connections, 6(8), 647-658. https://doi.org/10.1530/EC-17-0243
- 46. U.S. Food and Drug Administration. (2024, March 5). FDA clears first over-the-counter continuous glucose monitor [Press release]. Retrieved October 5, 2026, from https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor
- 47. U.S. Food and Drug Administration. (2026, August 27). Questions and answers on dietary supplements. Retrieved October 5, 2026, from https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements
- 48. U.S. National Library of Medicine. (2025, July 24). A study of tirzepatide (LY3298176) in participants with obesity or overweight (SURMOUNT-1) (Identifier NCT04184622). ClinicalTrials.gov. Retrieved October 5, 2026, from https://clinicaltrials.gov/study/NCT04184622
- 49. US Preventive Services Task Force, Davidson, K. W., Barry, M. J., Mangione, C. M., Cabana, M., Caughey, A. B., Davis, E. M., Donahue, K. E., Doubeni, C. A., Krist, A. H., Kubik, M., Li, L., Ogedegbe, G., Owens, D. K., Pbert, L., Silverstein, M., Stevermer, J., Tseng, C.-W., & Wong, J. B. (2021). Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement. JAMA, 326(8), 736-743. https://doi.org/10.1001/jama.2021.12531
- 50. Veronese, N., Watutantrige-Fernando, S., Luchini, C., Solmi, M., Sartore, G., Sergi, G., Manzato, E., Barbagallo, M., Maggi, S., & Stubbs, B. (2016). Effect of magnesium supplementation on glucose metabolism in people with or at risk of diabetes: A systematic review and meta-analysis of double-blind randomized controlled trials. European Journal of Clinical Nutrition, 70(12), 1354-1359. https://doi.org/10.1038/ejcn.2016.154
- 51. Vounzoulaki, E., Khunti, K., Abner, S. C., Tan, B. K., Davies, M. J., & Gillies, C. L. (2020). Progression to type 2 diabetes in women with a known history of gestational diabetes: Systematic review and meta-analysis. BMJ, 369, m1361. https://doi.org/10.1136/bmj.m1361
- 52. Wu, C., Ke, Y., & Nianogo, R. A. (2025). Trends in hyperinsulinemia and insulin resistance among nondiabetic US adults, NHANES, 1999-2018. Journal of Clinical Medicine, 14(9), 3215. https://doi.org/10.3390/jcm14093215
- 53. Zhao, J. V., Huang, X., Zhang, J., Chan, Y. H., Tse, H. F., & Blais, J. E. (2023). Overall and sex-specific effect of berberine on glycemic and insulin-related traits: A systematic review and meta-analysis of randomized controlled trials. The Journal of Nutrition, 153(10), 2939-2950. https://doi.org/10.1016/j.tjnut.2023.08.016
Comments